Long term outcomes of saphaneous vein graft intervention in elderly patients with prior coronary artery bypass graft

Ji-Hong WANG1,2, Wei LIU1, Xin DU1, Chang-Sheng MA1, Xue-Si WU1
1Department of Cardiology, Beijing An-Zhen Hospital, Capital Medical University, Beijing 100029, China
2Department of Cardiology, Beijing Ji-Shui-Tan Hospital, the 4th Clinical College of Peking University Health Science Center, Beijing 100035, China

Abstract

Objectives To investigate the procedure characteristics and long term follow-up of percutaneous coronary intervention (PCI) for saphaneous vein graft (SVG) lesions in the elderly patients. Methods From December 2005 to December 2011, 84 graft lesions were treated percutaneously. Seventeen were located at proximal anastomosis, 48 were located at SVG body, 19 were located at distal anastomosis. Primary endpoint was defined as major adverse cardiovascular events (MACE, composite of cardiac death, target vessel revascularization, acute myocardial infarction). Results The graft age was 6.7 ± 4.0 years. Most anastomosis lesions (80.0%) presented within one year post coronary artery bypass grafting (CABG). Proximal anastomosis lesion had the lowest successful rate for PCI compared with graft body and distal anastomosis lesions (70.6% vs 91.7%, 79.0%, P < 0.05). The distal embolic protection device was used in 19.1% of patients, most frequently used in body graft PCI (29.2%, P < 0.01). The diameter of the stent was smallest in distal anastomosis group (2.9 ± 0.4 mm, P < 0.05). The highest post dilatation pressure was required in the proximal anastomosis (17.8 ± 2.7 atm, P < 0.05). The patients were followed up for 24.3 ± 16.9 months. MACE occurred in 18.57% of patients. Incidence of MACE was highest among proximal anastomosis PCI (47.1% vs. body graft PCI 16.7%, distal anastomosis PCI 21.1%; P < 0.05). Old myocardial infarction was the predictive factor for the poor clinical outcomes (P = 0.04). Conclusions PCI of SVG lesions is feasible with lower success rate. PCI of ostial graft anastomosis lesions had the lowest procedure success rate and highest MACE rate compared with graft body and distal anastomosis lesions. Old myocardial infarction was a predictive factor of poor outcomes.

1 Introduction

It was known that about 50% of vein grafts developed significant stenosis or occlusion within 10 years following coronary artery bypass grafting (CABG). With the wide use of CABG over two decades in China, increasing number of patients with occluded graft revisited the hospital; a large proportion of them needs repeat revascularization. However, the treatment of saphenous vein graft (SVG) disease remains a major challenge. Repeated CABG carries a very high risk, especially for the elderly patients. Percutaneous coronary intervention (PCI) of SVG lesions was unavoidable even though it was associated with high rates of periprocedural complications and restenosis at long-term follow-up. In this study, we summarized our experience and outcomes of SVG intervention for elderly patients in the drug eluting stent (DES) era.

2 Methods

2.1 Patients and invasive strategy

In our registry from Beijing An-Zhen Hospital, between December 2005 and December 2011, a total of 762 consecutive patients with previous CABG underwent PCI for the treatment of coronary artery disease. Seventy of them were performed PCI for SVG. Informed consent was obtained from patients prior to undergoing urgent or selective PCI. Percutaneous graft stenting was performed via the femoral (using 6F, 7F, sheaths) or the radial arterial route (using 6F sheaths). The decisions to treat native vessels, choice of stents, use of glycoprotein IIb/IIIa inhibitors, vascular access, use of distal embolic protection devices (EPD) in vein graft PCI cases, and the use of diagnostic devices during the procedures were all made the discretion of ex-
performed by experienced operators. All patients received dual antiplatelet therapy (aspirin and clopidogrel) and an intravenous bolus injection of heparin (70 IU/kg body weight) before the procedure. Aspirin 100 mg daily was continued indefinitely after the procedure. The patients who had bare metal stents (BMS) were given clopidogrel 75 mg daily for a total period of 6 months. The patients receiving DES were given clopidogrel 75 mg daily for 12 months.

2.2 Definitions and clinical follow-up

The patients were followed up clinically or by telephone. The in-hospital mortality was defined as death during hospitalization associated with intervention. Following-up MACE composite of all-cause death, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR). Acute myocardial infarction was defined as prescribed in ESC/ACC (European Society of Cardiology/American College of Cardiology) third universal guideline of myocardial infarction. The significant stenosis was defined as any lesion of a major epicardial artery or branch vessel or graft (≥ 2.0 mm in diameter) which had a ≥ 50% stenosis of the lumen on angiographic assessment. Immediate angiographic success was defined as < 50% stenosis in all lesions attempted. Procedure success was defined as angiographic success without the occurrence of any major immediate complications (death, Q-wave MI, emergency redo CABG).

Major bleeding (not related to redo CABG) was defined as intracranial bleeding, access site bleed resulting in a hematoma ≥ 5 cm or requiring intervention/surgery, haemoglobin decreased by ≥ 3 g/dL with an overt source or by ≥ 4 g/dL without an overt source, any blood product transfusion, or reoperation for bleeding. The patient’s demographics, lesions treated, technical aspects of the procedure, procedure-related complications, adjunctive pharmacology, stent characteristics, and immediate procedure outcome were retrospectively studied. Cardiac enzymes following PCI were not routinely measured, except for patients with suspected perioperative infarction.

2.3 Statistics

Demographic, clinical, angiographic data were collected prospectively from the registry; continuous variables are expressed as mean ± SD and categorical variables as frequency (%). Previous report that clinical outcomes were different for vein graft lesion anatomies (anastomosis, body), we divided the patients into 3 groups according to anatomy (proximal, distal anastomosis, body graft). Continuous variables of procedure characteristics and clinical outcomes between different groups were compared by using the ANOVA test. Categorical variables were compared using Chi-square test. Finally, baseline risk factors (e.g., age, diabetes mellitus (DM), dyslipidemia, old MI, hypertension, years of CABG and sex) were analyzed for poor clinical outcomes by using Cox regression analysis. P < 0.05 was considered statistically significant and all reported P values are two tailed. Statistical analysis was performed using the SPSS Version 16 for Windows version (SPSS, Chicago, IL).

3 Results

Between December 2005 and December 2011, 70 patients with prior CABG and 84 SVG lesions were treated percutaneously. Baseline characteristics of these patients were listed in Table 1. Patient’s average age was 65.61 ± 8.70 years, 57.14% were male, and 25.71% of them presented with acute myocardial infarction.

Table 1. Clinical characteristics of patients undergoing SVG-PCI, n = 70.

|                      |       |
|----------------------|-------|
| Mean age, yrs        | 65.6 ± 8.7 |
| Gender               |       |
| Male                 | 40 (57.1%) |
| Graft age            | 6.7 ± 4.0 |
| Diagnosis at admission |       |
| Unstable Angina      | 42 (60.0%) |
| AMI                  | 18 (25.7%) |
| Stable angina        | 10 (14.3%) |
| Hypertension         | 53 (75.7%) |
| Diabetes             | 40 (57.1%) |
| Previous stent       | 12 (17.1%) |
| Previous MI          | 18 (25.7%) |

Data are presented as mean ± SD or n (%). AMI: acute myocardial infarction; MI: myocardial infarction; SVG: saphaneous vein graft; PCI: percutaneous coronary intervention..

Angiographic and intervention data were shown in Table 2. Totally, 84 SVG lesions were treated percutaneously. The intervened lesions located at aorta ostial anastomosis, graft body and distal anastomosis were 17, 48 and 19, respectively during the first year after CABG. Most anastomosis lesions (80.0%) presented within one year post CABG.

For lesions which were treated successfully, Judkins Right was the most common guide catheter (75.0%), followed by Amplatz left catheter (19.1%). BMW (Abbott Vascular; Abbott Park, Illinois) and super soft stabilizer (Cordis, Miami Lakes, FL) were the most commonly used workhorse guide wire in graft body lesions (60.4%), while Runthough wire (Terumo Medical Corporation) was mostly used in ostial graft lesion (41.2%). Hydrophic wire such as Whisper, Pilot wire series and chronic total occlusion (CTO) were used for lesions with severe calcified lesions.
wires such as miracle series (Abott vascular) and Choice PT (Boston Scientific; Natick, Massachusetts) were most mainly used in distal anastomosis lesions. A distal protection device was used in 19.1% of treated SVGs, generally used in graft body lesions (29.2%). No distal protection device was used in distal anastomosis lesions. A Filterwire (Boston Scientific) was used in 60% of distal EPD-treated lesions, Spider (ev3, Plymouth, Minnesota) in 40% of the patients. Eighty-four drug eluting stents were implanted in the SVG lesions. Sirolimus drug eluting stent were most frequently used DES. Direct stenting was performed in 19.0% of patients, and rarely used in distal anastomosis. More stents were implanted in body graft lesions. Average stent diameter was 3.4 ± 0.6 mm. Average post stent dilatation pressure was 15.2 ± 2.6 atm, with ostial anastomosis lesions needing the highest dilatation pressure (17.8 ± 2.7, \( P < 0.01 \)). Immediate angiographic success was 90.5%. The ostial graft lesions had the highest failure rate (21.1%). Four patients died in hospital (5.7%) during the index hospitalization. The course of death in the four patients was severe cardiogenic shock, non-reflow after stent deployment, cerebral stroke and gastric bleeding, respectively.

Clinical follow-up was available for 90% of patients either by face to face or telephone, the median period of follow up was 25 months. Results were listed in Table 3. Incidence of death, MI (including major periprocedural myocardial infarction), TVR were 7.1%, 2.9% and 8.6%, respectively during follow-up. Ostial anastomosis intervention had the highest rate of MACE (47.1%, vs. distal anastomosis 21.1%, graft body 16.67%, \( P < 0.05 \)). TVR was performed in 6 patients, with the indication of myocardial infarction in 2 cases and angina in 4 other cases.

---

**Table 2. Angiographic and procedure characteristics of SVG intervention.**

|                        | Total (n = 84) | Aortal ostial (n = 17) | Body (n = 48) | Distal anastomosis (n = 19) | \( P \) value |
|------------------------|---------------|------------------------|---------------|-----------------------------|---------------|
| Immediate failure      | 8 (9.5)       | 3 (17.6)               | 2 (4.2)       | 4 (21.1)                    | < 0.05        |
| Procedure failure      | 13 (15.5)     | 5 (29.4)               | 4 (8.3)       | 4 (21.1)                    |               |
| Target graft           |               |                        |               |                             |               |
| SVG-LAD                | 31 (36.9)     | 9 (52.9)               | 16 (33.3)     | 6 (31.6)                    |               |
| SVG-LCX                | 23 (27.4)     | 4 (23.5)               | 13 (27.1)     | 6 (31.6)                    |               |
| SVG-RCA                | 30 (35.7)     | 4 (23.5)               | 19 (39.6)     | 7 (36.8)                    |               |
| Jump graft             | 21 (25.0)     | 4 (23.5)               | 11 (22.9)     | 6 (31.6)                    |               |
| Total occlusion        | 14 (16.7)     | 4 (23.5)               | 8 (16.7)      | 2 (10.5)                    |               |
| Thrombus               | 12 (14.3)     | 2 (11.8)               | 8 (16.7)      | 2 (10.5)                    |               |
| Distal protection device| 16(19.1)      | 2 (11.8)               | 14 (29.2)     | 0                           | < 0.01        |
| Aspiration             | 8 (9.5)       | 1 (5.9)                | 6 (12.5)      | 1 (5.3)                     |               |
| Guide                  |               |                        |               |                             |               |
| AL                     | 16 (19.1)     | 4 (23.5)               | 8 (16.7)      | 4 (21.1)                    |               |
| JR                     | 63 (75.0)     | 11 (64.7)              | 39 (81.3)     | 13 (68.4)                   |               |
| Guidewire              |               |                        |               |                             |               |
| BMW/Supersoft          | 37 (44.1)     | 5 (29.4)               | 29 (60.4)     | 3 (15.8)                    |               |
| Runthrough             | 20 (23.8)     | 7 (41.2)               | 9 (18.8)      | 4 (21.1)                    |               |
| Pilot/Whisper          | 25 (29.8)     | 5 (29.4)               | 10 (20.8)     | 10 (52.6)                   | < 0.05        |
| Miracle/Cross IT       | 2 (2.4)       | 0                      | 0             | 2 (10.5)                    |               |
| Post dilatation        | 19 (22.6)     | 5 (29.4)               | 12 (25.0)     | 2 (10.5)                    |               |
| Pre dilatation         | 64 (76.2)     | 12 (70.6)              | 36 (75.0)     | 16 (84.2)                   |               |
| Direct stent           | 16 (19.1)     | 4 (23.5)               | 11 (22.9)     | 1 (5.3)                     |               |
| Stent diameter (mm)    | 3.4 ± 0.6     | 3.3 ± 0.6              | 3.5 ± 0.5     | 2.9 ± 0.4                   | < 0.05        |
| Maximum pressure (atm) | 15.2 ± 2.6    | 17.8 ± 2.7             | 14.4 ± 2.1    | 14.8 ± 3.2                  | < 0.01        |
| Stent length (mm)      | 25.6 ± 17.2   | 19.3 ± 8.1             | 30.2 ± 19.5   | 17.0 ± 6.0                  | < 0.05        |
| Average number         | 1.1 ± 0.6     | 0.9 ± 0.3              | 1.4 ± 0.6     | 0.6 ± 0.5                   | < 0.01        |

Data are presented as mean ± SD or n (%). AL: Amplatz Left; JR: Judkins Left; LAD: left descending artery; LCX: left circumflex; RCA: right coronary artery; SVG: saphaneous vein graft.
Table 3. Clinical outcomes of patient undergoing SVG-PCI.

|                       | Total (n = 70) | Ostial (n = 17) | Body (n = 48) | Distal (n = 19) | P value |
|-----------------------|---------------|----------------|--------------|----------------|---------|
| MACE                  | 13 (18.6)     | 8 (47.1)       | 8 (16.7)     | 4 (21.1)       | <0.05   |
| TVR                   | 6 (8.6)       | 3 (17.7)       | 3 (6.3)      | 2 (10.5)       |         |
| AMI                   | 2 (2.9)       | 1 (5.9)        | 1 (2.1)      | 2 (10.5)       |         |
| Death                 | 5 (7.1)       | 4 (23.5)       | 4 (8.3)      | 0              |         |

Data are presented as n (%). AMI: acute myocardial infarction; MACE: major adverse cardiac event, which includes death, non-fatal myocardial infarction and target vessel revascularization; SVG: saphenous vein graft; PCI: percutaneous coronary intervention; TVR: Target vascular revascularization.

Table 4. Baseline risk factors for poor outcomes.

| Factors                          | B    | SE   | Wald | Sig. | Exp (B) | 95.0% CI Exp(B) |
|----------------------------------|------|------|------|------|---------|-----------------|
| Diabetes mellitus                | 0.992| 0.646| 2.359| 0.125| 2.696   | 0.760 9.560     |
| Dyslipidemia                     | −0.315| 0.638| 0.244| 0.622| 0.730   | 0.209 2.550     |
| Sex                              | 0.541| 0.933| 0.336| 0.562| 1.717   | 0.345 10.693    |
| Previous history of PCI          | −1.065| 0.643| 2.746| 0.097| 0.345   | 0.098 1.215     |
| Old myocardial infarction        | 1.723| 0.839| 4.214| 0.040| 5.602   | 1.081 29.029    |
| Hypertension                     | 0.251| 0.586| 0.183| 0.669| 1.285   | 0.407 4.052     |
| Years after CABG                 | 0.111| 0.077| 2.063| 0.151| 1.117   | 0.960 1.299     |
| Age                              | −0.004| 0.034| 0.016| 0.898| 0.996   | 0.932 1.064     |

CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention.

The following baseline risk factors were entered as Cox regression models for poor clinical outcomes included age, sex, diabetes mellitus, dyslipidemia, hypertension, previous history of PCI, old myocardial infarction, years after CABG, the results were shown in Table 4. Old myocardial infarction was associated with higher MACE occurred (P = 0.04).

4 Discussion

Our results showed that PCI of SVG disease was feasible in elderly patients with a procedure which had a successful rate of 84.5%, MACE of 18.6% in a median in 2 year follow-up. SVG disease at anastomosis, especially aorta graft ostial anastomosis carried the worst clinical outcomes. The poor outcome of the percutaneous intervention of SVG ostial lesions could be explained by its pathophysiology. Anastomosis lesions usually happened within one year following CABG, probably due to thrombotic closure as a result of endothelial injury and the release of inflammatory cytokines during surgery. Technical factors, such as poor distal runoff, graft kinking, and small target vessel diameter, predisposed grafts to early occlusion. After the first month, exposure of the vein grafts to arterial pressure resulted in neointimal hyperplasia. This pathophysiologic process caused intimal damage, fibrosis, platelet aggregation, the release of growth factors, and smooth muscle cell proliferation. Due to the surgical technique and severe fibrosis of the anastomosis site, compared with body graft lesions, the PCI of anastomosis lesions might be technically more difficult, and needed more hydrophilic and stiff wires. Post stent dilation was always performed and needed more pressure to achieve a better stent expansion. Sometimes, due to the smaller vessel volume in anastomosis lesions, the stent could not be totally deployed and the stent size was relatively smaller. All these factors contributed to a high rate of restenosis and MACE.

After the first year, the main cause for graft failure was aggressive atherosclerotic narrowing which occurred over the already injured endothelium was. PCI of SVG carried a high risk of non-reflow phenomena. An early study showed that long-term survival after SVG intervention was poor, with one fourth of patients dying at median follow-up of 4 years. However, this happened in the early period when the DES and EPD were not commonly used. A more recent study indicated that the patients with SVG lesions remained a high-risk subgroup even in the era of drug-eluting stents, the mortality was 8.0% and MACE was 31.70% during follow-up of one year.

Some studies had revealed the benefit of the use of EPD in lowering in-hospital cardiovascular event rate and improving long-term outcomes. The AHA/ACC guidelines suggested mandatory use of EPD in SVG graft PCI.
However, the embolic device was not commonly used in our study (only constituted 13% of the study group). In some cases, lesion location was not favorable for EPD such as distal anastomosis. However, in other cases, the operators with the perception that some SVGs (e.g., those with relative focal or smooth lesions) have low enough risks to using of an EPD unnecessarily. A recent pool analysis of 3,958 graft intervention patients also showed that estimates of plaque volume and SVG degeneration could be a predictor of 30-day MACE in SVG percutaneous coronary intervention.\[10\] Therefore, the recognition of the predictor was very important in developing countries like China where cost-effectiveness is still an issue.\[11\]

In this study, we indentified that old MI was associated with higher MACE rate, which could be possibly due to large size of ischemic or unviable myocardium. This indicated PCI of SVG in such patients should be taken with precaution. Previous study also indicated PCI of SVG graft CTO had a less successful procedure rate, more follow up event and higher restenosis rate even with modern technique.\[12\] Therefore, PCI of SVG-CTO was not recommended. In this study, 16.7% of patients with occluded grafts were included. CTO lesions were common in aorta ostial lesions (23.5%), which might further decrease the successful rate of aorta ostial lesion PCI.

In this study, all stented patients were implanted with DES. Although it is still controversial, most studies favor DES over BMS in lowering the rate of restenosis and TVR.\[13–15\] In a pool analysis of the patient using DES, the MACE was 19.0%, mortality rate was 7.8%, and TVR was 12.0%, which are very similar to our results.\[14\]

Platelet glycoprotein IIb/IIIa receptor was rarely used in this study. Previous pooled analysis showed the lack of benefit from GP IIb/IIIa receptor inhibition as adjunctive treatment for SVG-PCI.\[16\] To date, there are no prospective randomized trials clearly demonstrating the benefits of GP IIb/IIIa inhibitors in SVG-PCI. However, there may be a role in their usage as adjuncts with certain embolic protection devices, such as the distal filtration devices.

Our study presented some limitations. First, the study was not randomized and prospective, the operator selection and inclusion criteria might have influenced the final results. Moreover, the sample size was relatively small. However, the clinical outcomes of PCI for anastomosis lesions in comparison with body graft lesions were rarely discussed previously, especially for the elderly patients.

Our study showed that PCI of SVG lesions was feasible with lower successful rate. PCI of ostial graft anastomosis lesions had the lowest successful rate and highest MACE rate in compared with graft body and distal anastomosis lesions. Old myocardial infarction was a predictive factor of poor outcomes.

References
1. Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: Results from a department of veterans affairs cooperative study. J Am Coll Cardiol 2004; 44: 2149–2156.
2. Lytle BW, Loop FD, Cosgrove DM, et al. Fifteen hundred coronary reoperations. Results and determinants of early and late survival. J Thorac Cardiovasc Surg 1987; 93: 847–859.
3. Nair S, Fath-Ordoubadi F, Clarke B, et al. Late outcomes of drug eluting and bare metal stents in saphenous vein graft percutaneous coronary intervention. EuroIntervention 2011: 6: 985–991.
4. Brilakis ES, Rao SV, Banerjee S, et al. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: A report from the national cardiovascular data registry. JACC Cardiovasc Interv 2011; 4: 844–850.
5. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020–2035.
6. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: Pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916–931.
7. Pucelikova T, Mehran R, Kirtane AJ, et al. Short- and long-term outcomes after stent-assisted percutaneous treatment of saphenous vein grafts in the drug-eluting stent era. Am J Cardiol 2008; 101: 63–68.
8. Lavi S, Ivanov J, Appleby CE, et al. Selective use of embolic protection devices during saphenous vein graft interventions: A single-center experience. Catheter Cardiovasc Interv 2010; 75: 1037–1044.
9. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction (updating the 2007 guideline): A report of the american college of cardiology foundation/american heart association task force on practice guidelines developed in collaboration with the american college of emergency physicians, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol 2011; 57: 1920–1959.
10. Coolong A, Baim DS, Kunzt RE, et al. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 2008; 117: 790–797.
11. Cohen DJ, Murphy SA, Baim DS, et al. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: Results from the safer trial. J Am Coll Cardiol 2004; 44: 1801–1808.
12 Al-Lamee R, Ielasi A, Latib A, et al. Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. *Am J Cardiol* 2010; 106: 1721–1727.

13 Alam M, Bandeali SJ, Virani SS, et al. Clinical outcomes of percutaneous interventions in saphenous vein grafts using drug-eluting stents compared to bare-metal stents: A comprehensive meta-analysis of all randomized clinical trials. *Clin Cardiol* 2012; 35: 291–296.

14 Hakeem A, Helmy T, Munsif S, et al. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: A comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. *Catheter Cardiovasc Interv* 2011; 77: 343–355.

15 Wiisanen ME, Abdel-Latif A, Mukherjee D, et al. Drug-eluting stents versus bare-metal stents in saphenous vein graft interventions: A systematic review and meta-analysis. *JACC Cardiovasc Interv* 2010; 3: 1262–1273.

16 Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein iib/iiia receptor inhibition as adjunctive treatment for percutaneous interventions of aorto-coronary bypass grafts: A pooled analysis of five randomized clinical trials. *Circulation* 2002; 106: 3063–3067.